Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IOVA NASDAQ:MIRM NASDAQ:PTCT NASDAQ:TGTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIOVAIovance Biotherapeutics$3.58-2.3%$3.79$1.64▼$5.63$1.60B0.6915.38 million shs8.24 million shsMIRMMirum Pharmaceuticals$110.46+1.2%$94.71$42.89▼$114.99$6.73B0.52910,046 shs534,147 shsPTCTPTC Therapeutics$73.52+0.1%$68.26$43.17▼$87.50$6.11B0.531.27 million shs247,611 shsTGTXTG Therapeutics$41.41-2.9%$33.74$25.28▼$44.65$6.35B1.682.12 million shs840,221 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIOVAIovance Biotherapeutics+2.81%-10.51%+5.78%+45.24%+104.47%MIRMMirum Pharmaceuticals+2.13%-0.84%+13.13%+7.01%+141.13%PTCTPTC Therapeutics-2.08%+10.37%+4.32%+3.90%+58.35%TGTXTG Therapeutics+0.26%+1.62%+26.22%+50.07%+27.81%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIOVAIovance Biotherapeutics$3.58-2.3%$3.79$1.64▼$5.63$1.60B0.6915.38 million shs8.24 million shsMIRMMirum Pharmaceuticals$110.46+1.2%$94.71$42.89▼$114.99$6.73B0.52910,046 shs534,147 shsPTCTPTC Therapeutics$73.52+0.1%$68.26$43.17▼$87.50$6.11B0.531.27 million shs247,611 shsTGTXTG Therapeutics$41.41-2.9%$33.74$25.28▼$44.65$6.35B1.682.12 million shs840,221 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIOVAIovance Biotherapeutics+2.81%-10.51%+5.78%+45.24%+104.47%MIRMMirum Pharmaceuticals+2.13%-0.84%+13.13%+7.01%+141.13%PTCTPTC Therapeutics-2.08%+10.37%+4.32%+3.90%+58.35%TGTXTG Therapeutics+0.26%+1.62%+26.22%+50.07%+27.81%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIOVAIovance Biotherapeutics 2.30Hold$8.43135.76% UpsideMIRMMirum Pharmaceuticals 2.93Moderate Buy$136.4223.50% UpsidePTCTPTC Therapeutics 2.57Moderate Buy$88.3620.18% UpsideTGTXTG Therapeutics 2.57Moderate Buy$52.5026.78% UpsideCurrent Analyst Ratings BreakdownLatest IOVA, TGTX, MIRM, and PTCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/11/2026PTCTPTC Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D)5/8/2026PTCTPTC Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$94.005/8/2026PTCTPTC Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$75.00 ➝ $90.005/8/2026PTCTPTC Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Perform$81.00 ➝ $82.005/8/2026PTCTPTC Therapeutics Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$86.00 ➝ $95.005/7/2026MIRMMirum Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D-) ➝ Sell (D)5/7/2026MIRMMirum Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$128.00 ➝ $142.005/7/2026MIRMMirum Pharmaceuticals TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$125.00 ➝ $145.005/7/2026MIRMMirum Pharmaceuticals Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingStrong-Buy$165.005/7/2026MIRMMirum Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$185.005/7/2026MIRMMirum Pharmaceuticals EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$138.00(Data available from 5/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIOVAIovance Biotherapeutics$285.61M5.59N/AN/A$1.62 per share2.21MIRMMirum Pharmaceuticals$521.31M12.92$0.05 per share2,096.54$3.98 per share27.75PTCTPTC Therapeutics$827.11M7.37$8.60 per share8.55($2.18) per share-33.72TGTXTG Therapeutics$700.35M9.05$2.73 per share15.18$3.81 per share10.87Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIOVAIovance Biotherapeutics-$390.98M-$0.95N/AN/AN/A-123.92%-50.17%-38.77%N/AMIRMMirum Pharmaceuticals-$23.36M-$13.61N/A380.89N/A-140.24%-11.28%-3.84%7/30/2026 (Estimated)PTCTPTC Therapeutics$682.64M-$2.33N/A45.95N/A-22.58%-362.45%-6.76%N/ATGTXTG Therapeutics$447.18M$2.8614.5014.90N/A65.95%88.73%43.44%N/ALatest IOVA, TGTX, MIRM, and PTCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026IOVAIovance Biotherapeutics-$0.19-$0.19N/A-$0.19$77.84 million$71.43 million5/7/2026Q1 2026PTCTPTC Therapeutics-$0.45-$0.03+$0.42-$0.03$217.42 million$272.55 million5/6/2026Q1 2026MIRMMirum Pharmaceuticals-$0.75-$13.43-$12.68-$13.43$148.21 million$159.88 million5/6/2026Q1 2026TGTXTG Therapeutics$0.23$0.12-$0.11$0.12$200.33 million$204.92 million2/26/2026Q4 2025TGTXTG Therapeutics$0.35$0.14-$0.21$0.14$192.15 million$192.57 million2/25/2026Q4 2025MIRMMirum Pharmaceuticals$0.02-$0.11-$0.13-$0.12$141.78 million$148.93 million2/24/2026Q4 2025IOVAIovance Biotherapeutics-$0.22-$0.18+$0.04-$0.18$81.61 million$86.77 million2/19/2026Q4 2025PTCTPTC Therapeutics-$0.21-$1.67-$1.46-$1.67$281.45 million$164.68 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthIOVAIovance BiotherapeuticsN/AN/AN/AN/AN/AMIRMMirum PharmaceuticalsN/AN/AN/AN/AN/APTCTPTC TherapeuticsN/AN/AN/AN/AN/ATGTXTG TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIOVAIovance BiotherapeuticsN/A3.603.15MIRMMirum Pharmaceuticals1.282.091.99PTCTPTC TherapeuticsN/A2.442.36TGTXTG Therapeutics1.285.815.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIOVAIovance Biotherapeutics77.03%MIRMMirum PharmaceuticalsN/APTCTPTC TherapeuticsN/ATGTXTG Therapeutics58.58%Insider OwnershipCompanyInsider OwnershipIOVAIovance Biotherapeutics7.80%MIRMMirum Pharmaceuticals14.36%PTCTPTC Therapeutics5.50%TGTXTG Therapeutics10.64%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIOVAIovance Biotherapeutics500446.50 million411.68 millionOptionableMIRMMirum Pharmaceuticals14060.98 million52.22 millionOptionablePTCTPTC Therapeutics1,41082.95 million78.39 millionOptionableTGTXTG Therapeutics290153.08 million136.80 millionOptionableIOVA, TGTX, MIRM, and PTCT HeadlinesRecent News About These CompaniesTG Therapeutics Stock Story Gains Interest In Nasdaq IndexMay 13 at 11:08 PM | kalkinemedia.comKTG Therapeutics' (NASDAQ:TGTX) Earnings Aren't As Good As They AppearMay 13 at 11:08 PM | finance.yahoo.comHistoric Signal Says This Biotech OutperformsMay 11 at 2:00 PM | schaeffersresearch.comWhy TG Therapeutics (TGTX) Is Up 27.4% After Raising 2026 Revenue Guidance On BRIUMVI StrengthMay 11 at 11:00 AM | finance.yahoo.comAssessing TG Therapeutics (TGTX) Valuation After Recent Share Price MomentumMay 10, 2026 | finance.yahoo.comQ2 EPS Estimates for TG Therapeutics Increased by AnalystMay 8, 2026 | marketbeat.comTGTX Q1 Earnings Miss, Sales Rise Y/Y, Stock Up on Raised 2026 ViewMay 7, 2026 | zacks.comTG Therapeutics Q1 Earnings Call HighlightsMay 7, 2026 | marketbeat.comTG Therapeutics: Q1 Earnings SnapshotMay 6, 2026 | seattlepi.comSTG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue GuidanceMay 6, 2026 | markets.businessinsider.comTG Therapeutics (TGTX) Q1 2026 Earnings TranscriptMay 6, 2026 | finance.yahoo.comTGTX stock hits fresh 52-week high – here’s why retail is bullish despite Q1 earnings missMay 6, 2026 | msn.comTG Therapeutics (NASDAQ:TGTX) Issues Quarterly Earnings ResultsMay 6, 2026 | marketbeat.comTG Therapeutics (NASDAQ:TGTX) Reaches New 1-Year High - Time to Buy?May 6, 2026 | marketbeat.comTG Therapeutics (TGTX) Q1 Earnings Lag EstimatesMay 6, 2026 | zacks.comVanguard Group Inc. Has $472.22 Million Stock Position in TG Therapeutics, Inc. $TGTXMay 6, 2026 | marketbeat.comTG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue GuidanceMay 6, 2026 | globenewswire.comTG Therapeutics to Host Conference Call on First Quarter 2026 Financial Results and Business UpdateApril 30, 2026 | globenewswire.comPictet Asset Management Holding SA Trims Stock Position in TG Therapeutics, Inc. $TGTXApril 30, 2026 | marketbeat.comTG Therapeutics, Inc. (NASDAQ:TGTX) Given Average Rating of "Moderate Buy" by AnalystsApril 30, 2026 | marketbeat.comFortrea Holdings Inc. (FTRE) Reports Next Week: Wall Street Expects Earnings GrowthApril 28, 2026 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIOVA, TGTX, MIRM, and PTCT Company DescriptionsIovance Biotherapeutics NASDAQ:IOVA$3.58 -0.09 (-2.32%) As of 02:29 PM Eastern This is a fair market value price provided by Massive. Learn more.Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.Mirum Pharmaceuticals NASDAQ:MIRM$110.46 +1.30 (+1.19%) As of 02:29 PM Eastern This is a fair market value price provided by Massive. Learn more.Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.PTC Therapeutics NASDAQ:PTCT$73.52 +0.06 (+0.08%) As of 02:29 PM Eastern This is a fair market value price provided by Massive. Learn more.PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.TG Therapeutics NASDAQ:TGTX$41.41 -1.24 (-2.91%) As of 02:29 PM Eastern This is a fair market value price provided by Massive. Learn more.TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Cisco’s Vertical Rally May Still Be in the Early Innings Dividend Growth or High Yield: The Income Investor's Bet Nebius Upside Expands as AI Feedback Loop Intensifies Oklo Stock Could Be Ready for Another Massive Run Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell Qualcomm Stock Doubles: New Era? Or Another False Start? D-Wave Earnings Looked Weak, But Investors May Be Missing This Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
